Analysts Update CRISPR Therapeutics Price Targets

Brokerages updated CRISPR Therapeutics' price targets in mid-February: Morgan Stanley on Feb. 17 raised its target to $33 from $32 but kept an Underweight rating; JPMorgan on Feb. 16 cut its target to $67 from $69 while maintaining Overweight; and Citi on Feb. 16 raised its target to $80, reaffirming Buy after Casgevy sales topped estimates. These moves reflect revenue beats and anticipated 2026 pipeline catalysts.